Home » Stocks » CLSD

Clearside Biomedical, Inc. (CLSD)

Stock Price: $4.92 USD -0.29 (-5.57%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $4.99 +0.07 (1.42%) Jul 30, 7:39 PM
Market Cap 296.53M
Revenue (ttm) 3.83M
Net Income (ttm) -22.65M
Shares Out 57.04M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $4.92
Previous Close $5.21
Change ($) -0.29
Change (%) -5.57%
Day's Open 5.24
Day's Range 4.86 - 5.30
Day's Volume 477,290
52-Week Range 1.25 - 7.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

3 days ago - GlobeNewsWire

Looking for the best penny stocks to watch right now? Check these 7 out The post Which Penny Stocks Are Investors Buying Right Now?

Other stocks mentioned: MUX, NGD, NXE, PHX
3 weeks ago - PennyStocks

In a recent pennystocks.com article, we covered 5 Penny Stocks on Reddit for Your June 2021 Watchlist. This piece is a continuation, as more and more valuable penny stocks continue to come to light. Rig...

Other stocks mentioned: BOXL, CFMS, PTIX, UXIN
1 month ago - PennyStocks

Analysts are excited about the biotech's investigational treatment for a common eye disorder.

1 month ago - The Motley Fool

Looking for penny stocks to buy on Reddit? Check these 4 out for your watchlist The post 4 Penny Stocks Reddit Traders Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other stocks mentioned: CFMS, OBLN, TELL
1 month ago - PennyStocks

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Today, investors in CLSD stock are seeing gains of nearly 50% as the company announced positive results from one of its clinical trials. The post CLSD Stock: The Big News Lifting Clearside Biomedical To...

1 month ago - InvestorPlace

Shares of Clearside Biomedical, Inc. (NASDAQ: CLSD) are skyrocketing Tuesday morning after the company announced positive safety results for a treatment for eye diseases. If Clearside makes it to the $4...

1 month ago - Benzinga

Clearside Biomedical Inc (NASDAQ: CLSD) has announced positive safety results from Cohort 1 (n=6) of OASIS Phase 1/2a trial of CLS-AX (axitinib injectable suspension) for neovascular age-related macular...

Other stocks mentioned: AMD
1 month ago - Benzinga

- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events -

1 month ago - GlobeNewsWire

ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

1 month ago - GlobeNewsWire

PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global ey...

Other stocks mentioned: BHC
1 month ago - PRNewsWire

Shares of Clearside Biomedical (NASDAQ:CLSD) rose after the company reported Q1 results. Quarterly Results Earnings per share decreased 85.71% over the past year to ($0.13), which missed the estimate of...

2 months ago - Benzinga

- Recent New Drug Application Resubmission for XIPERE TM

2 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Presentations support proprietary suprachoroidal space delivery platform and programs Presentations support proprietary suprachoroidal space delivery platform and programs

2 months ago - GlobeNewsWire

ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision...

2 months ago - GlobeNewsWire

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

2 months ago - GlobeNewsWire

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visi...

3 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the ...

4 months ago - Zacks Investment Research

- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed -

4 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

- Initial Safety Data from First Cohort Expected Mid-2021 -

4 months ago - GlobeNewsWire

ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

5 months ago - GlobeNewsWire

ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

5 months ago - GlobeNewsWire

ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

5 months ago - GlobeNewsWire

- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders -

5 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).

5 months ago - Zacks Investment Research

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Does Clearside Biomedical, Inc. (CLSD) have what it takes to be a top stock pick for momentum investors? Let's find out.

6 months ago - Zacks Investment Research

ALPHARETTA, Ga., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

6 months ago - GlobeNewsWire

ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

6 months ago - GlobeNewsWire

Clearside Biomedical is aiming to make ocular gene therapy accessible. XIPERE NDA resubmission and potential approval in 2021 triggering a $15 million payment from partner Bausch Health.

6 months ago - Seeking Alpha

Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg ann...

Other stocks mentioned: AAPL, CAT, DIS, DOW, EIGR, INTC, JNJ ...
6 months ago - Seeking Alpha

ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visi...

8 months ago - GlobeNewsWire

ALPHARETTA, Ga., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

8 months ago - GlobeNewsWire

Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

- Initiation of Phase 1/2a Trial of CLS-AX ( axitinib injectable suspension ) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector ® Ongoing by  ...

8 months ago - GlobeNewsWire

ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...

9 months ago - GlobeNewsWire

Clearside Biomedical (CLSD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

9 months ago - Zacks Investment Research

Presented the most robust aggregate dataset of suprachoroidal clinical injections demonstrating reliability and consistency of procedure Presented the most robust aggregate dataset of suprachoroidal cli...

10 months ago - GlobeNewsWire

ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve v...

10 months ago - GlobeNewsWire

ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi...

10 months ago - GlobeNewsWire

ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve v...

10 months ago - GlobeNewsWire

- New intellectual property covers suprachoroidal administration with therapeutic agents including CLS-AX and XIPERE - - New intellectual property covers suprachoroidal administration with therapeutic a...

11 months ago - GlobeNewsWire

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0.00% and -75.47%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manufacturer f...

11 months ago - GlobeNewsWire

- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 -

11 months ago - GlobeNewsWire

ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vis...

11 months ago - GlobeNewsWire

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in... [Read more...]

Industry
Biotechnology
IPO Date
Jun 2, 2016
CEO
George Lasezkay
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
CLSD
Full Company Profile

Financial Performance

In 2020, CLSD's revenue was $7.89 million, an increase of 263.28% compared to the previous year's $2.17 million. Losses were -$18.21 million, -40.82% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is 11.75, which is an increase of 138.82% from the latest price.

Price Target
$11.75
(138.82% upside)
Analyst Consensus: Buy